Lindbrook Capital, LLC Inhibrx, Inc. Transaction History

Lindbrook Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$14.5 - $38.0 $493 - $1,292	-34 Reduced 33.01%	69 $2,000
Q3 2023 Oct 25, 2023	BUY	$15.75 - $26.31 $1,622 - $2,709	103 New	103 $1,000
Q4 2022 Jan 24, 2023	BUY	$20.18 - $33.33 $665 - $1,099	33 Added 80.49%	74 $0
Q3 2022 Nov 10, 2022	SELL	$11.58 - $24.73 $1,204 - $2,571	-104 Reduced 71.72%	41 $1,000
Q2 2022 Aug 01, 2022	BUY	$8.52 - $25.26 $570 - $1,692	67 Added 85.9%	145 $2,000
Q1 2022 Apr 21, 2022	BUY	$19.89 - $43.18 $1,551 - $3,368	78 New	78 $2,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.